Introduction: In the absence of a licensed formulation in many countries worldwide, ADV6209, an innovative 2 mg/ml oral solution of midazolam containing cyclodextrin, has been developed for moderate sedation in paediatric patients. Population pharmacokinetics for ADV6209 is reported. Methods: Plasma concentration data were collected from 37 paediatric patients and 12 healthy adults recruited in a single dose, open-label phase II pharmacokinetic study and in a single dose, randomised, open-label twoperiod crossover bioavailability study, respectively. Data were analysed using non-linear mixed effect modelling. Plasma concentrations of midazolam were described by a two-compartment model. An additional one-compartment model was added for α-hydroxymidazolam. Results: The body weight covariate was found to have a significant impact on midazolam and α-hydroxymidazolam clearance, and on midazolam volume of distribution. The population pharmacokinetic model indicated that 77% of the midazolam dose was absorbed within 30 min after oral administration. Parameter estimations for a subject of 34 kg indicated values of midazolam clearance of 34.7 l·h − 1 , a central volume of distribution of 27.9 l and a peripheral volume of distribution of 413 l. A higher metabolic ratio and a higher midazolam clearance per body weight were observed in the youngest group of subjects, in accordance with literature data. The clearance per body weight of α-hydroxymidazolam remained constant over the different age groups. Conclusion: Pharmacokinetic parameters were close to those reported in the literature with midazolam extemporaneous oral solutions or syrups, demonstrating that cyclodextrin had no significant effect on measured parameters.
Introduction
Midazolam is a short acting hypnotic-sedative imidazobenzodiazepine drug with anxiolytic and amnestic properties. When given orally, midazolam produces a quick (< 45 min) moderate sedation with no significant impact on recovery time that makes it extremely useful as premedication to reduce preoperative anxiety before anaesthesia and for short therapeutic or diagnostic procedures in paediatric patients (Cox et al., 2006) . Considering the lack of available oral medications for moderate sedation in children in most European countries, ADV6209, an innovative oral solution of midazolam for children from 6 months of age, was developed. The formation of a gamma-cyclodextrin:midazolam complex was used to improve the solubility and the palatability of our midazolam formulation (Marçon et al., 2009) .
Midazolam is a class I drug (highly soluble, highly permeable) according to the biopharmaceutical classification system. Solubility enhancers like cyclodextrins are not expected to improve its bioavailability whereas its pharmacokinetics and especially its disposition kinetics may be modified by factors influencing the gastric emptying (Wu and Benet, 2005) . In a previous phase I pharmacokinetic study, we have demonstrated that bioavailability of ADV6209 (F = 39.6%) was not significantly enhanced by gamma-cyclodextrins in healthy adults, as compared to average reported bioavailabilities ranging from 20 to 48% (Guittet et al., 2017) . Pre-systemic metabolism by intestinal and hepatic cytochromes P450 (CYP3A) remains the main factor limiting oral bioavailability of midazolam (Thummel et al., 1996) . Midazolam is widely distributed in the body and eliminated through metabolisation by CYP3A as two active metabolites. The predominant metabolite, α-hydroxymidazolam, and 4-hydroxymidazolam are both secondarily transformed by glucuronide conjugation via UDB-glucuronyltransferase (Seo et al., 2010) and subsequently excreted in the urine with a minor amount of unchanged drug and unconjugated metabolites (Heizmann and Ziegler, 1981) .
Within the paediatric population, the developmental change in metabolic and elimination clearance mechanisms may account for high inter-individual and important age-related variability in CYP3A substrate pharmacokinetics (Alcorn and Mcnamara, 2002; Reed et al., 2001) . A population pharmacokinetic model for continuous infusion of midazolam within the critically ill neonates population showed that due to immature CYP3A4 enzyme activity midazolam clearance was 1.6 times lower in neonates younger than 39 weeks of gestation than in those with a gestational age of > 39 weeks (Burtin et al., 1994) . A further population pharmacokinetic model for intravenous administration of midazolam in neonates indicated that a major change in maturation of CYP3A activity occurs during the first month of life, and body weight, seemed to be the most significant covariate explaining the increased metabolic activity after intravenous administration (Ince et al., 2013) . There are only few population studies describing the impact of age on disposition kinetics of midazolam after oral administration, and none of these adequately describes absorption lag times or double peaks observed on individual pharmacokinetic profiles (Belle et al., 2002; Guittet et al., 2017; Guo et al., 2011; H.-Y. Wang et al., 2016) .
The aim of the present study was to assess the pharmacokinetic characteristics of the ADV6209 oral formulation in paediatric patients from 6 months to 18 years old in order to support dosing recommendations. Population pharmacokinetic modelling was performed to characterise the concentration-time course of midazolam and its main active metabolite, α-hydroxymidazolam, and to evaluate the changes in clearance and volume of distribution in the different age groups.
Material and methods

Midazolam:gamma-cyclodextrin formulation
ADV6209 is an innovative 0.2% (w/v) oral solution of midazolam, developed to improve the solubility and to mask the well-known bitter taste of the drugs in water so that the solution may respond to specifications concerning dosing and acceptability in the targeted population, as previously published (Marçon et al., 2009) . It contains gammacyclodextrin, which reduces midazolam bitterness and enhance its aqueous solubility by forming an inclusion complex with the drug. Additionally, sucralose was chosen for its bitterness masking effect (Ley, 2008) and orange flavour for taste improvement (Walsh et al., 2014) . The pH of the formulation ranges from 3.8 to 4.0.
Pharmacokinetic studies
The present work is based on data obtained from a phase 2 paediatric study and a phase 1 adult study, both performed with ADV6209 oral solution of midazolam. Both studies were conducted in accordance with Good Clinical Practice and the Declaration of Helsinki. Study protocols and informed consent forms were approved by French regional ethics committees on human research and by the French national agency for medicine and health products (ANSM). Written informed consent was obtained from the parents or legal guardians of all the children and adolescents and from the subjects themselves, when possible.
The phase 2 study was an open, monocentric, uncontrolled pharmacokinetic (PK) study in children from 6 months to 17 years old requiring premedication before general anaesthesia. During the study, 37 paediatric patients were enrolled in 3 age groups: 8 infants between 6 and 23 months, 17 children between 2 and 11 years, and 12 adolescents between 12 and 17 years of age. All paediatric patients (either sex) for whom surgery under general anaesthesia was planned with an ASA (American Society of Anaesthesiology) status of I or II and with a body mass index between the 3rd and 97th percentile were included. Pregnant girls and patients presenting with any condition that could prevent their participation in the study (including known hypersensitivity to benzodiazepines) were excluded.
All subjects received a single 0.3 mg/kg midazolam dose of ADV6209, without exceeding a total dose of 10 mg (0.269 mg/kg on average). In order to facilitate dose adjustments, an enteral syringe was provided for administration of the correct volume of liquid.
Anaesthesia was induced by opioids, inhaled anaesthetics, and analgaesics. Any concomitant medications causing potential metabolic interactions with midazolam (particularly CYP3A4 inhibitors and inducers) were strictly avoided.
Serial blood samples were collected for determination of plasma concentrations of midazolam and α-hydroxymidazolam. One blood sample was taken from adolescent patients just before drug administration, and then 12 additional blood samples were taken at 0.083, 0.17, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6 and 9 h post-dose. Four blood samples were taken from infants and young children: just before, and then at 3 randomised time points out of the 12 possible (see adolescent subgroup), in order to obtain a blood sample from each of the expected absorption, peak and elimination phases for each subject, covering up to 9 h after administration. Children were distributed evenly according to their age.
To support modelling of midazolam PK in children, plasma concentrations of midazolam and α-hydroxymidazolam, obtained during an adult phase 1 study in 12 healthy adult subjects receiving 15 mg of ADV6209 administered directly into the mouth, were used. Full methodology has been reported elsewhere (Guittet et al., 2017) .
Analytical method
Blood samples were analysed at SGS Cephac Europe (St Benoît, France). The analytical procedure involved a liquid/liquid extraction with methyl tert-butyl ether followed by reverse phase liquid chromatography analysis of the extract coupled with tandem mass spectrometric detection (LC-MS/MS). The method was linear for both analytes, midazolam and α-hydroxymidazolam, from 0.100 to 100 ng·ml − 1 . Adequate intra-batch and inter-batch accuracy was demonstrated, with mean concentrations of both analytes within ± 14% of the nominal values. Precision was also acceptable, with intra-batch and inter-batch CV values below 11% for midazolam and below 12% for α-hydroxymidazolam. The specificity of the method was verified against endogenous matrix components and against each analyte. No significant carryover effect was observed. The extraction recovery of the whole process was higher than 90% for midazolam, higher than 96% for α-hydroxymidazolam and higher than 86% for the internal standard. No significant matrix effect was observed.
Before injection of each batch of samples, system suitability was verified using two levels of reference samples. The precision of the analysis had to be within the acceptability level (CV ≤ 10%).
Population pharmacokinetic modelling
Population PK analysis was performed by non-linear mixed effects modelling using Monolix 3.1R2 (Lixoft, Antony, France) (Chan et al., 2011) . The model was developed in a stepwise manner. First, an exploratory graphical analysis of the midazolam and α-hydroxymidazolam concentration-time profiles in adults and, adolescents (rich data profiles), was performed using R version 2.16 (R Core Team, 2017) . PK data in adolescents were analysed, using WinNonlin version 5.3 (Pharsight Corporation Inc., California, USA). The model was developed using these rich data profiles. Sparse data from the young children data set were then added and the model was fine-tuned. Finally, significant covariates were considered to produce the final model.
The α-hydroxymidazolam concentration-time profiles were analysed by adding a one-compartment model to the midazolam model. Since α-hydroxymidazolam was not administered separately, the volume of distribution of this compartment could not be estimated and was fixed to the volume of distribution of midazolam, based on the observation that after separate intravenous administrations of midazolam and α-hydroxymidazolam, the volumes of distribution of midazolam (60 l, 1.6 l·kg − 1 ) and α-hydroxymidazolam (54 l, 0.92 l·kg − 1 ) are comparable (Hotz et al., 2000; Mandema et al., 1992) . Also, based on the literature, the metabolic rate constant from the midazolam central compartment to the α-hydroxymidazolam compartment was fixed to 0.269 h − 1 (Johnson et al., 2002) . A log-normal random distribution (i.e. inter-individual variability) of the model parameters was assumed.
To describe the changes in the pharmacokinetics across age groups, the covariate effect of actual body weight on midazolam clearance and volume of distribution and on α-hydroxymidazolam clearance was tested. The covariate effect was implemented on the model parameters in a multiplicative way as a power function (e.g. (BW/BWpop) power with BWpop = reference value). The covariate-parameters relationship was considered as statistically significant for p-value < 0.01 and covariate implemented model selection was performed on the basis of a log-likelihood ratio test. The goodness of fit was evaluated throughout the model development process. The estimation was performed on logtransformed midazolam and α-hydroxymidazolam concentrations assuming normal distribution of additive residual errors. Concentrations below the limit of quantification (BLQ) were taken into account using the CENS item in the data configuration of Monolix. All BLQ concentrations observed were within 10 min after drug administration.
Results
The final dataset used for the analysis of the oral data consisted of the 49 subjects from the phase 1 and phase 2 studies, with 873 records containing 363 midazolam and 363 α-hydroxymidazolam plasma concentrations (Table 1 ). There were no withdrawals, no data (i.e. dose, concentrations and covariates) were missing and all the observations were included in the analysis.
Graphical and non-compartmental pharmacokinetic analyses
Mean concentration time profiles of midazolam and α-hydroxymidazolam in adolescents are depicted in Fig. 1 . At the tested dose, the median peak time (T max ) was 0.75 h (ranging from 0.25 to 6.00 h) for midazolam and 0.88 h (0.25 to 3.08 h) for α-hydroxymidazolam. The mean ( ± SD) peak concentration (C max ) values were 40.8 ± 18.6 ng·ml The terminal half-life (t 1/2 ) was 3.6 ± 2.5 h for midazolam and 2.12 ± 0.64 h for α-hydroxymidazolam, with terminal elimination rate constant (λ Z ) values of 0.26 ± 0.1 h − 1 and 0.35 ± 0.09 h
Inspection of individual midazolam concentration-time profiles indicated that midazolam absorption occurred in several phases in some individuals (Fig. 2) .
Model development
The complex absorption profiles observed in adolescents required multiple input compartments to better describe them. Visual inspection of rich concentration-time profiles in adults and adolescents also indicated that the disposition of midazolam after oral administration would be best modelled by a two-compartment model.
The base population pharmacokinetic model consisted of an open two-compartment (CEN and PER) model with three depot compartments (DEP1, DEP2 and DEP3), each receiving a part (P 1 , P 4 and P 5 respectively) of the total dose absorbed, and to which an additional compartment (OH) was added to describe the α-hydroxymidazolam concentration-time profiles (Fig. 3) . To represent pre-systemic The individual relative bioavailability factors (P 1 + P 4 + P 5 = 100%) as a function of lag time and age for the three absorption phases indicated that the first two absorption phases (P 1 and P 4 ) were very close to each other and most of the midazolam dose (mean P 1 + P 4 = 77%) was absorbed within 30 min after oral administration. A delayed fraction (mean P 5 = 23%) was absorbed between 1 and 5 h after administration.
The average amount of α-hydroxymidazolam formed during presystemic metabolism relative to the amount of midazolam that reached Fig. 3 . Schematic representation of the final midazolam and α-hydroxymidazolam population pharmacokinetic model. DUR 1 is the infusion duration of the drug in the absorption compartment 1 (DEP1) (h), T lag n are the lag-times (h) between drug administration and entry of the drug in the systemic circulation, BIO n and P n are relative bioavailability parameters and factors (P 1 + P 4 + P 5 = 1), DEP n are absorption compartments, K 12 , K 42 and K 52 are absorption rate constants (h DUR is the infusion duration of the drug in the absorption compartment 1 (DEP1) (h), T lag n are the lag-times (h) between drug administration and entry of the drug in the systemic circulation, BIO n and P n are relative bioavailability parameters and factors (P 1 + P 4 + P 5 = 1), DEP n are absorption compartments, The mean ( ± SE) allometric exponents describing the changes in midazolam clearance and volume of distribution as a function of body weight (centred to 34 kg) were 0.62 ± 0.12 and 1.16 ± 0.14 and that describing the changes in α-hydroxymidazolam clearance as a function of body weight was 1.01 ± 0.10. The population pharmacokinetic model estimated the oral clearance of midazolam at 34.7 l·h − 1 for a subject of 34 kg. The mean oral clearance of α-hydroxymidazolam was estimated at 40.6 l·h
, assuming a systemic metabolic rate fraction from midazolam to α-hydroxymidazolam of 0.269. The estimated central and peripheral distribution volumes were 27.9 l and 413 l, respectively (Table 2) .
Goodness-of-fit plots demonstrated that the final model for midazolam and α-hydroxymidazolam described the data reasonably well (Figs. 6 & 7) . No significant deviations from the unity line were detected and only a small under-prediction was observed for high α-hydroxymidazolam concentrations at the individual level.
Discussion
Population pharmacokinetic model
After single administration of ADV6209 oral solution, midazolam and α-hydroxymidazolam pharmacokinetic parameters were obtained by a non-compartmental method in adolescents, for whom rich data were available. The parameters obtained were in close agreement with those already reported in the literature at similar doses for oral administration of midazolam (Payne et al., 1989; Reed et al., 2001) .
A complex population pharmacokinetic model was developed using non-linear mixed-effects modelling including data from paediatric patients from 6 months of age to 17 years old and healthy adult subjects. Previously published midazolam population pharmacokinetic analyses have used a two-compartment model to fit intravenous data, but without taking into account α-hydroxymidazolam concentration (Burtin et al., 1994; de Wildt et al., 2003; Ince et al., 2013) .
The major structural aspects of the model used in the present analysis (absorption of midazolam, pre-systemic metabolism of midazolam to α-hydroxymidazolam, systemic metabolism of midazolam to α-hydroxymidazolam and distribution and clearance of midazolam and α-hydroxymidazolam) were derived from a previous publication with oral data (Johnson et al., 2002) , where both midazolam and α-hydroxymidazolam have been considered in the model, and adapted for the multiple absorption phases observed with some of the rich data profiles. Due to the large number of parameters required to fit the multiple and variable absorption phases and to the sparse sampling scheme in about half of the subjects, important shrinkage (η > 50%) was observed in the post-hoc distribution of the model parameters. Therefore, the covariate analysis was restricted and was only performed for the effect of body weight on clearance and central volume of distribution.
Absorption
Despite multiple absorption phases, midazolam was absorbed rapidly following oral administration, in accordance with literature data (Allonen et al., 1981; Bornemann et al., 1985; Reed et al., 2001 ), although important inter-individual variability was observed in the peak Fig. 4 . Midazolam clearance as a function of body weight (left) and age (right) in the final population pharmacokinetic model (red, blue, green, yellow dots for infants, children, adolescents, adults' values respectively; the black line is a smooth through the data). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) time values, which was related to the presence of a second apparent peak in certain subjects, corresponding to the third absorption phase (P 5 ). The lag-time and fraction absorbed for this delayed absorption were higher in children than in adults and did not seem to be correlated with the time of anaesthesia in the paediatric patients. Double-peak phenomenon and delayed absorption as represented in the population pharmacokinetic model with ADV6209 have already been reported with oral administration of midazolam (Belle et al., 2002; Guo et al., 2011; H.-Y. Wang et al., 2016) or other benzodiazepines (Y. Wang et al., 1999) . Double peaks are believed to be related to a delayed gastric emptying. It has been reported that BCS class I drugs such as midazolam may have their pharmacokinetics altered by gastric emptying (Wu and Benet, 2005) and that delayed gastric emptying may produce a double peak (Oberle and Amidon, 1987) . Additionally, it has been shown that midazolam could induce a delayed gastric emptying and thus produce its own absorption interaction (Inada et al., 2004) . It should be kept in mind that this phenomenon may be accentuated with drugs such as opioids (Greiff and Rowbotham, 1994) and in premature and neonate populations (Bartelink et al., 2006) .
Clearance and metabolic ratio
As expected by the difference observed in hepatic and intestinal CYP3A expression and activity within these age groups (de Wildt et al., 1999) , midazolam clearance (CL/F) was lower in infants than in adults.
The α-hydroxymidazolam clearance (CL OH /F) was also lower in infants than in adults. α-hydroxymidazolam is mainly metabolised by UGT 1A4, 2B4 and 2B7 (Seo et al., 2010) . It has been reported that UGT 1A4 is mature from 4 months of age (Miyagi and Collier, 2007) , and that UGT 2B7 expression and activity increase throughout age groups, which could explain this increase (Zaya et al., 2006) . When reported to body weight, the difference between subpopulations was illustrated by the higher clearance of midazolam in younger compared with older subjects; this is consistent with previous published data following oral administration (Table 3) . When estimated for a 70 kg adult, oral clearance (CL/F = 56.9 L/H) was within the range of previously reported results for oral administration of midazolam to healthy adults (CL/F = 46.6-84.8 L/H) (Thummel et al., 1996; Vanhove et al., 2016) . This can be explained by the larger liver size normalised to body weight in younger children (Murry et al., 1995) . The clearance per body weight of α-hydroxymidazolam remained relatively constant with age. In addition to the systemic metabolism of midazolam to α-hydroxymidazolam, the pre-systemic metabolism from midazolam to α-hydroxymidazolam was estimated at 17.7% of the amount of midazolam that reached the systemic circulation and contributed to about 40% of α-hydroxymidazolam exposure. The α-hydroxymidazolam active metabolite was present in high concentrations in the first 1.5 to 2 h following oral administration. The amount of α-hydroxymidazolam formed during pre-systemic metabolism of midazolam as a function of age was relatively constant and close to the value of 17,8% reported by Johnson (Johnson et al., 2002) . The higher metabolic ratio observed in infants compared to adolescents can be explained by a lower renal clearance of α-hydroxymidazolam relative to midazolam at young age, as suggested by the literature (Bornemann et al., 1985; Reed et al., 2001) . A higher covariate effect of body weight on α-hydroxymidazolam clearance was observed compared with midazolam clearance. The metabolic ratio found with healthy adults was significantly higher than that previously observed after IV administration (0.313 vs 0.127) (Mandema et al., 1992) , as expected by the higher metabolism due to the pre-systemic metabolism with the oral route. Fig. 7 . Goodness of fit plot for the final model with covariates (α-hydroxymidazolam). 
Volume of distribution
The mean central volume of distribution per body weight increased only very slightly with age and was close to previous findings with oral administration (Table 3) or with intravenous dataset (Burtin et al., 1994; de Wildt et al., 2003) . When the central volume of distribution was considered it was perfectly correlated with body weight as depicted on Fig. 5. 
Allometric scaling
During model development, fixed allometric exponents describing the changes in midazolam clearance and volume of distribution as a function of body weight on CL (0.75) and V2 (1) for the model with midazolam only were also tested. Since the objective functions for the fixed (−2 × log-likelihood: 589.98) or estimated (−2 × log-likelihood: 576.81) parameters were close to each other we decided to keep the model in which the exponents where estimated. These estimated exponents describing the changes in midazolam clearance and volume of distribution as a function of body weight (0.62 and 1.16 respectively) included in their 95% confidence intervals the classical allometric scaling factors (i.e. 0.75 for clearance and 1.0 for volume of distribution) (Mahmood, 2014) , supporting the proposal of an administered dose directly proportional to body weight. It has also been demonstrated that when excluding the neonates and premature age groups, the 0.75 exponents could adequately predict the midazolam clearance in a paediatric population (mean age 5.2 years) (Mahmood, 2006) . Regarding peripheral volume of distribution (V3), the precision of this parameter was initially very poor (47% RSE, Table 2 ). This may be due to the fact that measures were limited in time in all population subgroups and especially in the paediatric population, which rendered difficult its estimation and limited any covariate effect on this parameter (fixed or estimated). The graphical analysis of the distribution of the V3 parameter as a function of body weight and age in the final model did not indicate any relationship. Since this parameter had very little significance within the available data and did not indicate a relationship with body weight or age, it was decided and deemed reasonable not to apply any covariate effect on this parameter.
Conclusion
The population pharmacokinetic model described the concentration-time profiles of midazolam and α-hydroxymidazolam observed in adults, adolescents, children and infants after administration of ADV6209 oral solution of midazolam. The multiple absorption phases observed were captured and the pre-systemic metabolism of midazolam to α-hydroxymidazolam was demonstrated.
Due to the shrinkage in the estimated individual model parameters, the model may present some limitations for population predictions, but can be used for simulation of mean profiles in infant to adult sub-populations, considering that the values obtained for the main pharmacokinetic parameters are similar to those reported in the literature.
Finally, measured PK parameters of ADV6029 (midazolam solution containing cyclodextrin) were close to those reported in the literature with other midazolam formulations, such as extemporaneous oral solutions or syrups.
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